. Author manuscript; available in PMC: 2017 Dec 10.

Published in final edited form as: Am J Hematol. 2017 Apr 29;92(6):569–582. doi: 10.1002/ajh.24750

Table 2.

Completed Phase 1 or Phase 2 clinical studies^* supported by a number of sponsors and employing a variety of CO-administration mechanisms

Clinical Trial	Description/Indication	CO Product
Phase 1	Single Dose Safety (Normal Volunteers)	Inhaled gas¹⁰⁷
Phase 1	Repeat Dose (10 Days) Safety (Normal Volunteers)	Inhaled gas¹⁰⁷
Phase 1	Single Dose Safety (Normal Volunteers)	CORM (Sanguinate^™)¹¹⁰
Phase 1b	Repeat Dose Safety (Sickle Cell Disease)	CORM (Sanguinate^™)¹⁰⁹
Phase 1b	Repeat Dose Safety (Sickle Cell Disease)	CORM (MP4CO)¹⁰⁸
Phase 2	Chronic Obstructive Pulmonary Disorder	Inhaled gas¹¹¹
Phase 2	Experimental Endotoxemia	Inhaled gas¹¹²
Phase 2	Mitochondrial Biogenesis (skeletal muscle)	Inhaled gas¹¹³